

WHAT IS CLAIMED IS:

1                   1.     A selective cytotoxic reagent comprising an onc protein having  
2     measurable ribonucleolytic activity joined to an antibody directed against a surface marker  
3     expressed by a B cell.

1                   2.     The reagent of claim 1, wherein the onc protein has the amino acid  
2     sequence of SEQ ID NO:1.

1                   3.     The reagent of claim 1, wherein the onc protein is produced by  
2     recombinant means.

1                   4.     The reagent of claim 3, wherein the onc protein has the amino acid  
2     sequence of SEQ ID NO:3

1                   5.     The reagent of claim 3, wherein the onc protein is encoded by the  
2     nucleic acid molecule identified as SEQ ID NO:2.

1                   6.     The reagent of claim 1, wherein the antibody is a monoclonal  
2     antibody.

1                   7.     The reagent of claim 6, wherein the monoclonal antibody is  
2     humanized.

1                   8.     The reagent of claim 7, wherein the monoclonal antibody is a single  
2     chain antibody.

1                   9.     The reagent of claim 1, wherein the antibody is specific for B cell  
2     lymphomas.

1                   10.    The reagent of claim 9, wherein the antibody is selected from the  
2     group consisting of RFB4 and LL2.